AIMD

Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th

Retrieved on: 
Thursday, February 1, 2024

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that Jack Lu, the Company’s Director of Corporate Development, will present live at the Small-Cap Growth Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on February 7, 2024.

Key Points: 
  • SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that Jack Lu, the Company’s Director of Corporate Development, will present live at the Small-Cap Growth Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on February 7, 2024.
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients

Retrieved on: 
Tuesday, September 19, 2023

Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients.

Key Points: 
  • Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients.
  • An estimated 24,000 HIV-seropositive Americans suffer from chronic oral warts.
  • Ainos plans to seek a pre-IND meeting with the U.S. FDA, with plans to advance VELDONA into a Phase 3 study for oral warts.
  • We estimate in excess of a $1 Billion global market opportunity for the company.

Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond

Retrieved on: 
Tuesday, August 15, 2023

Ainos has developed a technology called AI Nose designed to identify Volatile Organic Compounds (VOC), and we see this as potentially revolutionary for the future of healthcare.

Key Points: 
  • Ainos has developed a technology called AI Nose designed to identify Volatile Organic Compounds (VOC), and we see this as potentially revolutionary for the future of healthcare.
  • To view the full announcement, including downloadable images, bios, and more, click here .
  • Horizon Insights, we see two big trends right now in healthcare - the emergence of Artificial Intelligence, or AI platforms, and the growing prevalence and acceptance of Telehealth.
  • The fees for these services vary on a per-client basis and are subject to the number and types of services contracted.

Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals

Retrieved on: 
Monday, November 21, 2022

SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has published preclinical data demonstrating the potential of its low-dose oral interferon-alpha (IFNα) formulation, VELDONA®, as treatment candidates for the two most common medical conditions for dogs and cats. The preclinical data can be accessed here.

Key Points: 
  • The Company initially applied VELDONA to feline coronavirus (FCoV)-infected fcwf-4 (feline microphage) systems to determine potency and dose translation.
  • Based on VELDONA's effective antiviral efficacy,the Company is planning an expansion of its use for the treatment of humans to treatment of animals.
  • Ainos is designing dose-finding field studies to identify optimal VELDONA dose via oromucosal administration for feline FCGS and canine CAD.
  • FCGS is a severe oral mucosal inflammatory disease afflicting cats, while CAD is an inflammatory skin disease found in dogs.

Ainos Reports Unaudited Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022

SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the third quarter ended September 30, 2022.

Key Points: 
  • SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the third quarter ended September 30, 2022.
  • Gross profit was US$581,742, up 124% year over year, representing a gross margin of 33.1% in the third quarter of 2022.
  • Hui-Lan Wu, Chief Financial Officer of Ainos, commented, "Year-over-year top-line growth of 384.2% was driven by strong sales of our COVID19 Antigen Self-Test Kits during the third quarter.
  • Cost of revenues was US$1,176,032 in the third quarter of 2022, compared with US$103,638 in the same period of 2021.

Vertex wins U.S. Navy contract valued up to $280 million

Retrieved on: 
Monday, October 3, 2022

Training is critical in keeping Naval Aviation at a high level of readiness, said Ed Boyington, President and CEO of The Vertex Company.

Key Points: 
  • Training is critical in keeping Naval Aviation at a high level of readiness, said Ed Boyington, President and CEO of The Vertex Company.
  • The Vertex Company provides timely high-quality maintenance of training aircraft, enabling our military to meet their readiness objectives.
  • As part of the Aircraft Intermediate Maintenance Department, or AIMD, contract, Vertex will provide intermediate or I-level maintenance for U.S. Navy training aircraft including the T-6 Texan, T-44 Pegasus, T-45 Goshawk, TH-57 Sea Ranger and TH-73 Thrasher.
  • The contract also includes I-level maintenance for specific items used by the U.S. Navy and Marine Corps iconic Blue Angels flight demonstration team.

Wireless Power Is Here -- Could It Save Your Life?

Retrieved on: 
Monday, May 23, 2022

NEW YORK, May 23, 2022 /PRNewswire/ -- Benzinga Partner Network -- WiFi gets you wireless internet. WiGL, pronounced wiggle, could one day very soon get you wireless electrical power.

Key Points: 
  • WiGL , pronounced wiggle, could one day very soon get you wireless electrical power.
  • What if wireless power networks could be an alternative source of filling up those batteries, or one day replacing batteries all together?
  • The Virginia-based startup says it is working to get people to ditch cords and wires via the power of wireless power networks.
  • In short, WiGL is building networks of wireless power that could also help in the field of medicine.

PHC Receives First EU-MDR Certification, Delivers Motorized Drug Injection Device Enabling More Efficient Patient-Friendly Treatment of Arthritis and Other Inflammatory Conditions

Retrieved on: 
Monday, April 18, 2022

The device, called APP-1000*1, is designed to provide simple, precise, and monitored drug injections in the home setting for conditions including rheumatoid arthritis.

Key Points: 
  • The device, called APP-1000*1, is designed to provide simple, precise, and monitored drug injections in the home setting for conditions including rheumatoid arthritis.
  • APP-1000 is a class IIa*2 portable medical device, manufactured at PHC IVDs Wakimachi plant in Japan.
  • It allows patients to self-inject TNF inhibitors automatically at a touch of a button with no measurement or preparation required.
  • The device comes equipped with an LCD screen with illustrated guidance to make it easier for patients to use.